Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259264 | 0.80 | MAPT (0.33) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL10092876 | 0.77 | NOS3 (0.34) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL19407165 | 0.77 | CYP11B2 (0.40) | — | |
| SCHEMBL9610936 | 0.75 | DAO (0.46) | — | |
| SCHEMBL18517237 | 0.75 | HCAR2 (0.35) | — | |
| SCHEMBL25006036 | 0.74 | CNR1 (0.31) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL17828154 | 0.74 | CYP11B2 (0.34) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL22955141 | 0.73 | CYP3A4 (0.35) | — | |
| SCHEMBL240843 | 0.72 | SMYD3 (0.39) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL21316558 | 0.68 | ESR1 (0.35) | SMYD3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | SMYD3 4290/4885CHRNB2 217/4885CHRNA4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.